According to new research, positive discordance as measured by a glycation ratio of glucose management indicator and haemoglobin A1c (GMI/A1c)

On June 26 2023, the American Diabetes Association® (ADA) presented Carmella Evans-Molina, MD, PhD, Eli Lilly Professor of Paediatric Diabetes,

In the symposium Engineering and Site Consideration for Cell Therapy on Monday, June 25, panellists discussed cell therapy and the

Approximately fifty percent of patients with endstage renal disease in developed countries have diabetes, according to the National Institutes of

There is accumulating evidence regarding the cardiovascular benefits of sodium-glucose cotransporter 2 (SGLT2) inhibitors and glucagon-like peptide 1 (GLP-1) receptor

This paper was presented by Drs Jean Lu, Cheng Yi Yuan, Yee W. Kong, Emma Netzer, Huanping Wu, Thomas Seidl,

This paper was presented by Drs Carel Le Roux, Oren Steen, Kathryn J. Lucas, Elena Startseva, Anna Unseld, Anita M.

When a patient’s therapeutic objectives are not met, therapeutic inertia is the failure to initiate, intensify, or sometimes de-intensify therapy.

In November 2022, the U.S. Food and Drug Administration approved teplizumab, a CD3- directed monoclonal antibody and the first drug

In a new feature at the 83 Scientific Sessions, six diabetes innovators will have the opportunity to present their ideas